SCHEMBL1830692

SCHEMBL1830692

O=C(/C=C/c1cccc(Cl)c1)c1cc(Br)ccc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.67
AR P10275 3/20 0.64
MAPT P10636 6/20 0.61
NPSR1 Q6W5P4 4/20 0.61
MAOB P27338 3/20 0.61
MAOA P21397 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.58
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 3/20 0.57
TDP1 Q9NUW8 3/20 0.57
MEN1 O00255 2/20 0.57
LMNA P02545 2/20 0.57
POLB P06746 2/20 0.57
ALOX12 P18054 2/20 0.57
RECQL P46063 2/20 0.57
XBP1 P17861 1/20 0.57
HSP90AA1 P07900 2/20 0.56
THRB P10828 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1822452 1.00 STAT3 (0.67) STAT3ARMAPTNPSR1MAOB
SCHEMBL5424561 0.85 MAOB (0.74) STAT3ARMAPTNPSR1MAOB
SCHEMBL5424563 0.85 MAOB (0.74) STAT3ARMAPTNPSR1MAOB
SCHEMBL2376112 0.84 MAPT (0.74) ARMAPTNPSR1MAOBMAOA
SCHEMBL7956659 0.84 MAPT (0.74) ARMAPTNPSR1MAOBMAOA
SCHEMBL7957952 0.84 AR (0.64) ARMAPTMAOBMAOAKDM4E
SCHEMBL7961159 0.84 MAPT (0.61) ARMAPTNPSR1MAOBMAOA
SCHEMBL25243464 0.83 MAOB (0.73) ARMAPTNPSR1MAOBMAOA
SCHEMBL6699171 0.83 MAOB (0.73) ARMAPTNPSR1MAOBMAOA
SCHEMBL6699166 0.83 MAOB (0.73) ARMAPTNPSR1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2013-11-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
EP-2324032-A2 INHIBITORS OF BETA-SECRETASE Vitae Pharmaceuticals, Inc. (US) 2011-05-25 EP disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP STAT3 4488/4885AR 4331/4885MAPT 61/4885
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APP STAT3 4488/4885AR 4331/4885MAPT 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.